Kuros Biosciences Ltd. (CH:KURN)
:KURN
Want to see CH:KURN full AI Analyst Report?
Top Page
Kuros Biosciences
(KURN)
Select Model
Select Model
Rating:56Neutral
Price Target:
CHF21.00
▼(-25.43% Downside)
Action:Reiterated
Date:03/13/26
The score is primarily supported by strong operating progress (rapid revenue growth, high gross margins, and a 2025 profitability inflection) and a low-leverage balance sheet. It is held back by deteriorating 2025 cash flow (negative operating and free cash flow), a weak trend versus moving averages, and a very elevated P/E multiple.
Positive Factors
Sustained Revenue Scaling
Rapid, sustained revenue growth over multiple years shows the company has successfully expanded market penetration and procedure adoption for MagnetOs. This scale reduces per-unit fixed costs, supports operating leverage, and creates a larger base for future margin expansion and reinvestment.
Negative Factors
Weak Cash Conversion
Negative operating and free cash flow despite reported earnings indicates working-capital or investment drag and poorer cash conversion. If this persists, the business will face higher near-term funding needs, increasing execution risk and potential dilution or financing costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Scaling
Rapid, sustained revenue growth over multiple years shows the company has successfully expanded market penetration and procedure adoption for MagnetOs. This scale reduces per-unit fixed costs, supports operating leverage, and creates a larger base for future margin expansion and reinvestment.
Read all positive factors
Kuros Biosciences (KURN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF812.45M
Dividend YieldN/A
Average Volume (3M)128.87K
Price to Earnings (P/E)483.1
Beta (1Y)1.39
Revenue Growth59.85%
EPS GrowthN/A
CountryCH
Employees122
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.04
Shares Outstanding39,439,423
10 Day Avg. Volume110,510
30 Day Avg. Volume128,868
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF38.00Price Target Upside34.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.31
Revenue Forecast (FY)CHF200.67M
Kuros Biosciences Business Overview & Revenue Model
Company Description
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, th...
How the Company Makes Money
Kuros primarily makes money by selling its synthetic bone graft products (notably MagnetOs) to hospitals and surgical centers for use in procedures such as spinal fusion and other bone repair applications. Revenue is generated from product sales v...
Kuros Biosciences Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
46
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 121.30M | 75.56M | 33.56M | 17.99M | 13.81M |
| Gross Profit | 104.79M | 62.03M | 23.94M | 10.77M | 10.07M |
| EBITDA | 10.13M | -561.00K | -6.84M | -8.84M | -5.29M |
| Net Income | 2.12M | -3.72M | -13.73M | -14.60M | -7.54M |
Balance Sheet | |||||
| Total Assets | 107.21M | 84.54M | 71.46M | 82.95M | 91.34M |
| Cash, Cash Equivalents and Short-Term Investments | 15.66M | 17.46M | 14.21M | 24.07M | 28.62M |
| Total Debt | 3.94M | 1.79M | 2.14M | 1.91M | 8.93M |
| Total Liabilities | 40.28M | 25.79M | 14.75M | 14.09M | 14.36M |
| Stockholders Equity | 66.93M | 58.75M | 56.71M | 68.86M | 76.98M |
Cash Flow | |||||
| Free Cash Flow | -2.40M | 2.03M | -9.17M | -7.75M | -5.83M |
| Operating Cash Flow | -377.87K | 3.14M | -8.84M | -7.35M | -5.45M |
| Investing Cash Flow | -2.03M | -1.11M | -326.00K | -400.00K | -374.00K |
| Financing Cash Flow | 1.17M | 1.34M | -171.00K | 3.22M | 6.08M |
Kuros Biosciences Technical Analysis
Neutral
28.16
Price Trends
21.64
Negative
23.63
Negative
25.62
Negative
Market Momentum
-0.33
Negative
48.78
Neutral
72.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:KURN, the sentiment is Neutral. The current price of 28.16 is above the 20-day moving average (MA) of 20.64, above the 50-day MA of 21.64, and above the 200-day MA of 25.62, indicating a bearish trend. The MACD of -0.33 indicates Negative momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 72.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:KURN.
Kuros Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF611.91M | 18.63 | ― | ― | 11.43% | -48.80% | |
56 Neutral | CHF812.45M | 483.13 | -7.82% | ― | 59.85% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | CHF1.18B | -5.16 | ― | ― | 35.80% | 24.01% | |
50 Neutral | CHF251.75M | -19.66 | ― | ― | -63.05% | -187.61% | |
44 Neutral | CHF231.02M | -4.09 | -301.13% | ― | 97.32% | -11.07% | |
43 Neutral | CHF122.34M | -2.03 | -51.05% | ― | -100.00% | 9.23% |
* Healthcare Sector Average
CH:KURN
Kuros Biosciences
20.20
-4.64
-18.68%
CH:MOLN
Molecular Partners AG
3.15
0.07
2.27%
CH:BSLN
Basilea Pharmaceutica
49.30
-1.30
-2.57%
CH:IDIA
Idorsia Ltd
4.51
2.55
130.47%
CH:NWRN
Newron Pharmaceuticals SpA
12.02
4.90
68.82%
CH:SANN
Santhera Pharmaceuticals Holding
15.02
3.38
29.04%
Kuros Biosciences Corporate Events
Kuros Biosciences posts 51% Q1 sales surge on MagnetOs growth and manufacturing expansion
Apr 14, 2026
Kuros Biosciences reported a 51% year-on-year increase in total product sales to USD 43.4 million for the first quarter of 2026, driven almost entirely by MagnetOs, which also grew 51% to USD 42.9 million. EBITDA improved to USD 2.9 million and ad...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.